3Mendiluce A,Bustanmante J,Martin D. Cystatin C as a market of renal function in kidney transplants[J].{H}TRANSPLANTATION PROCEEDINGS,2005,(09):3844-3847.
7Bengtsson E,To F,Grubb A. Absence of the protease inhibitor Cystatin C in inflammatory cells results in larger plaque area in plaque regression of apoE-deficientmice[J].{H}ATHEROSCLEROSIS,2005,(01):45-53.
8Sukhova GK,Wang B,Libby P. Cy statin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotien E-nullmice[J].{H}CIRCULATION RESEARCH,2005.368-375.
10Kestenbaum B,Rudser KD,de Boer IH. Differences in kidney function and incident hypertension:the multiethnic study of atherosclerosis[J].{H}ANNALS OF INTERNAL MEDICINE,2008,(07):501-508.
5Fraley AE, Tsimikas S. Clinical applications of circulating oxidized low- density lipoprotein biomarkers in cardiovascular disease [ J ]. Curt Opin Lipidol, 2006,17 (5) :502 - 509.
6Tsimikas S, Lau HK, Han KR, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a) : short - term and long - term immunologic responses to oxidized low- density lipoprotein[ J]. Circulation,2004,109(25 ) : 3164 - 3170.
7Bokenkamp A, Herget - Rosenthal S, Bokenkamp R. Cystatin C, kidney function and cardiovascular disease [J]. Pediatr Nephrol,2006,21 (9) : 1223 -1230.
8Lay IS, Hsieh CC, Chiu JH, et al. Salvianolic acid B enhances in vitro angiogenesis and improves skin flap survival in Sprague - Dawley rats [ J ]. J Surg Res, 2003,115 (2) : 279 - 285.
9Bengtsson E, To F, Hakansson K, et al. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E - deficient mice[J ]. Arteriosclcr Thromb Vasc Biol,2005,25(10) : 2151 -2156.
10Jormsjo S, Wuttge DM, Sirsjo A, et al. Differential expression of cysteine and aspartic proteases during progres- sion of atheroselerosis in apolipoprotein E -deficient mice [J].Am J Pathol, 2002, 161(3) : 939 -945.
5Cross DS,Mccarty CA,Hytopoulos E,et al.Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts[J].Curr Med Res Opin,2012,28(.11):1819-1830.
6Wei D,Peng J J,Gao H,etal.Digoxin Downregulates NDRGl and VEGF through the Inhibition of HIF-Ialpha under Hypoxic Conditions in Human Lung Adenocarcinoma A549 Cells[J].Int J Mol Sci,2013,14(4):7273-7285.
7Lei L,Mason S, Liu D,et al.Hypoxia-inducible factor-dependent degeneration,failure,and malignant transformation of the heart in the absence of the von Hippel-Lindau protein[J].Mol Cell Biol,2008,28(11):3790-3803.
8Albrecht M,Zitta K,Bein B,et al,Remote ischemic preconditioning regulates HIF-Ialpha levels,apoptosis and inflammation in heart tissue of cardiosurgical patients:a pilot experimental study[J],Basic Res Cardiol,2013,108(1):314.
9Knorr M,Munzel T,Wenzel P.Interplay of NK cells and monocytes in vascular inflammation and myocardial infarction[J].Front Physiol,2014,5:295.
